Dr. Otto Warburg
It has long been understood that cancer cells have a different metabolism from that of normal cells, but this was... More
HPV vaccine doesn’t provide herd immunity or crossprotection
WASHINGTON – The prevalence of human papillomavirus (HPV) types 16 and 18 has significantly decreased, but only among... More
ASCT still a player for multiple myeloma
Even in this era of novel therapies for multiple myeloma, for patients with newly diagnosed disease, autologous stem... More
Dr. Bradley Greenhaw
ORLANDO – A commercially available melanoma gene expression test had a negative predictive value of 98% for metastasis,... More
Statins, but not aspirin, linked to lower pancreatic cancer risk
SAN DIEGO – Statin use, but not aspirin use, showed a protective effect against pancreatic ductal adenocarcinoma in a... More
Dr. Claire Blanchard
BALTIMORE – Patients who have recurrent adrenocortical carcinoma appear to have one option to increase their survival:... More
Dr. Jeremy Sugrue
LOS ANGELES – A multicenter of patients who had low anterior resection with stapled anastomosis for rectal cancer found... More
Dr. Mouad Edderkaoui
SAN DIEGO – The experimental drug Metavert was effective in a mouse model of aggressive pancreatic cancer, and phase I... More
Dr. Prasad G. Iyer
SAN DIEGO – A quick, inexpensive, and well-tolerated sponge-on-a-string esophageal biopsy, combined with methylated DNA... More
Shown is a 3D illustration of the thyroid gland.
BALTIMORE – Biopsy results from a commercially available genetic test for ruling out malignancy of thyroid nodules may... More
Dr. Veroushka Ballester-Vargas
SAN DIEGO – It has been challenging to identify reliable biomarkers for Lynch syndrome colorectal neoplasms, but that... More
This is a micrograph of a diffuse large B cell lymphoma.
Maintenance therapy with enzastaurin, an experimental agent directed against B-cell malignancies, did not improve... More
Dr. Bradley J. Monk
A novel strategy of knocking down tumor vasculature and keeping it from getting back up significantly reduced the risk... More
Dasatinib bests imatinib on molecular, cytogenic response rates in CML
Overall survival and progression-free survival were similar at 5 years in chronic myeloid leukemia patients receiving... More
High ER expression + high RS spells high risk for late distant recurrence
The combination of a 21-gene recurrence score and quantitative estrogen receptor expression may help clinicians... More

Reviews

Ciaran M Fairman et al
Previous findings suggest that exercise is a safe and efficacious means of improving physiological and psychosocial outcomes in female breast cancer survivors. To date, most research has focused on post-treatment interventions. However, given that th... More »
 

Reviews

Jeremy M O’Connor et al
The cost of cancer care is increasing, with important implications for the delivery of high-quality, patient-centered care. In the clinical setting, patients and physicians express a desire to discuss out-of-pocket costs. Nevertheless, both groups fe... More »
 
Felicia Schanche Hodge et al
Background Caregivers play a special role in the management and control of cancer-related pain. For American Indians with cancer, caregivers can contribute to patient education, medication compliance, and can facilitate communication between the pati... More »
 
Matthew H Bertke et al
Background There are limited data on the prognostic significance of human papillomavirus (HPV) status in relation to traditional risk factors for head and neck squamous-cell carcinoma (HNSCC) in the postoperative setting. Objective To clarify the im... More »
 

Features

James R Berenson et al; with Leslie T Busby
Multiple myeloma (MM) is a bone marrow- based malignancy of plasma cells that is diagnosed in over 30,000 patients annually in the United States. Despite the many recent advances in the treatment of MM, it remains an incurable disease. Thus, the need... More »
 

Features

Jane de Lartigue, PhD
The pace of drug development for multiple myeloma was dizzying in 2015, with 5 regulatory approvals for the treatment of relapsed/refractory disease, 3 in a single month. As we stand on the brink of another paradigm shift in the management of this di... More »
 

From the Editor

David H Henry, MD, FACP
As you read this month’s May issue of the Journal of Community and Supportive Oncology, the world will be making plans to attend the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Two things will happen there: invest... More »
 

From the Editor

Debra Patt, MD, FACP
We are in a time of transition in oncology. During this period of remarkable innovation in oncology treatments we have substantial improvements in cancer care, but we also have higher health care costs and a growing population of older patients who h... More »
 
click me